相关实验视频

Updated: Mar 12, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

托法西提尼布与环胺相比在早期扩散性皮肤全身性硬化症中的有效性和安全性:一项随机对照试验

Nabil Amin Khan¹, Ariful Islam¹, Abu Shahin¹

¹Department of Rheumatology, Bangladesh Medical University (BMU), Dhaka, BGD.

|March 11, 2026

概括

与环胺相比,托法西替尼在早期扩散性皮肤系统性硬化症 (dcSSc) 中显著降低了皮肤厚度. 这种JAK抑制剂显示为dcSSc患者更安全,更有效的治疗选择.

科学领域:

类风湿病学类风湿病学
免疫学免疫学免疫学
皮肤病学皮肤病学

背景情况:

扩散性皮肤系统性硬化症 (dcSSc) 是一种自身免疫性疾病,其特征是皮肤变厚和器官损伤.
目前用于早期dcSSc的治疗方法在有效性和安全性方面存在局限性.

研究的目的:

评估托法西提尼布与环胺相比在治疗早期dcSSc.的疗效和安全性.
评估托法西提尼布对皮肤评分,疾病活性和功能状态的影响.

主要方法:

这是一项开放的随机对照试验,涉及46名患有早期dcSSc的患者.
随机分配患者接受托法西提尼布 (每天两次服用5毫克) 或环胺 (每月500毫克/平方米).
主要终点是24周修饰罗丹皮肤得分 (mRSS) 的变化;次要终点包括DAS28,CRP,ESR和B-HAQ得分.

主要成果:

托法西替尼在12周和24周的mRSS显著减少,与环胺相比 (p <0.05).
无论是DAS28-ESR还是DAS28-CRP,都显示出托法西提尼布组的显著减少.
虽然功能状态 (B-HAQ) 和FVC变化在托法西替尼治疗中显示出数值改善,但它们在不同组之间没有统计学意义.

结论:

托法西替尼在早期dcSSc.皮肤厚度降低方面是有效的.
托法西替尼比环胺在疗效和安全性方面具有优势.
需要进一步研究托法西替尼作为早期dcSSc的治疗方法.

关键词:

环酸胺的使用方法德马德斯 (dmards) 是一个名为德马德斯的公司.美国的Mr.系统性硬化症系统性硬化症托法西提尼布 (tofacitinib) 是一种

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...